Enregistrement :
11
de
13
(2023-01-30
à
2023-12-31)
Subvention, Contribution ou autre avantage financier
BioVectra received funding to allow the corporation to expand API and scaled biologics capacity in the Atlantic Canada region from Canada’s Strategic Innovation Fund (SIF) in the amount of $21.1M, all of which was collected during 2021 fiscal year. Subsequent to 2021, BioVectra applied and received approval in for funding to expand existing technologies in biomanufacturing and mRNA vaccine production totaling $39.8M from the Strategic Innovation Fund (SIF). Both SIF funding agreements are in the form of grants and repayable loan. BioVectra also sought funding from provincial governments in both Nova Scotia and PEI to support capital investment, labor cost and other operational costs associated with the biomanufacturing and mRNA production. Those funding agreements came in the form of non-repayable grant, tax incentives and repayable contribution. BioVectra was awarded and collected funding in full in the amount of $1.87M from NRC-IRAP to develop a concept for the manufacturing of COVID-19 vaccines